« Back
Home /
Cediranib (maleate)

Cediranib (maleate)

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neural Development Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	50 mg
Item no.	HY-13049-50mg
Targets	VEGFR; Autophagy; PDGFR
CASRN	857036-77-2
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	566.58
Clinical_Information	Phase 3
Manufacturers Research_Area	Cancer
Solubility	DMSO : ≥ 45 mg/mL\|H2O : 2 mg/mL (ultrasonic)
Manufacturers Target	Autophagy; PDGFR; VEGFR
Isoform	PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13049-50mg-safety-datasheet.pdf